- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Digital Phenotype Could Change Healthcare
The "digital phenotype," a catch-all term for the trail of relevant health data people leave behind in their interactions with the internet, social media, and technology, has largely untapped potential for the early detection of various conditions.
A new editorial in Nature Biotech poses the idea of the “digital phenotype” as a catch-all term for the trail of relevant health data people leave behind in their interactions with the internet, social media, and technology, which has largely untapped potential for the early detection of various conditions.
CareMore Chief Medical Officer Sachin Jain, MD, submitted the paper along with Harvard Medical School colleagues Brian Powers, an MD candidate, Jared Hawkins, PhD, and John Brownstein, PhD, whose Computational Epidemiology Group has done a lot of work in the area of digital phenotyping already.
“People are increasingly leaving a footprint of their health status through technology, including social media, forums, online communities, wearable technologies, and mobile devices,” Dr Jain said in a statement. “This information all has clinical value to a physician. The challenge is being aware of it and knowing how to access and interpret it.”
Read more at MobiHealthNews: http://bit.ly/1bMrKBU
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
